FDA approvals in November include Lilly’s Zepbound for chronic weight management, plus AstraZeneca’s first-in-class Truqap for advanced forms of HR+ breast cancer. Bristol Myers Squibb’s Augtyro is approved for ROS1-positive non-small cell lung cancer, and Takeda’s Fruzaqla is okayed for metastatic colorectal cancer. Zituvimet is a new oral combo option for type 2 diabetes and Ogsiveo is cleared for aggressive desmoid tumors. Plus, Adzynma is the first treatment for cTTP, a rare blood clotting disorder.
Featured News FDA approvals in November include Lilly’s Zepbound for chronic weight management, plus AstraZeneca’s first-in-class Truqap for advanced forms of HR+ breast cancer. Bristol Myers Squibb’s Augtyro is approved for ROS1-positive non-small cell lung cancer, and Takeda’s Fruzaqla is okayed for metastatic colorectal cancer. Zituvimet is a new oral combo option for type 2 diabetes and Ogsiveo is cleared for aggressive desmoid tumors. Plus, Adzynma is the first treatment for cTTP, a rare blood clotting disorder.
|
---|
|
New Drug Approvals The following drugs have recently been approved by the FDA. - Ogsiveo (nirogacestat) Tablets
Date of Approval: November 27, 2023 Treatment for: Desmoid Tumors Press Release | Approval History
- Truqap (capivasertib) Tablets
Date of Approval: November 16, 2023 Treatment for: Breast Cancer Press Release | Approval History
- Ryzneuta (efbemalenograstim alfa-vuxw) Injection
Date of Approval: November 16, 2023 Treatment for: Neutropenia Associated with Chemotherapy Press Release | Approval History
- DefenCath (taurolidine and heparin) Catheter Lock Solution
Date of Approval: November 15, 2023 Treatment for: Prevention of Catheter-Related Bloodstream Infections Press Release | Approval History
- Augtyro (repotrectinib) Capsules
Date of Approval: November 15, 2023 Treatment for: Non-Small Cell Lung Cancer Press Release | Approval History
- Ixchiq (chikungunya vaccine, live) Injection
Date of Approval: November 9, 2023 Treatment for: Chikungunya Disease Prevention Press Release | Approval History
- Adzynma (ADAMTS13, recombinant-krhn) Lyophilized Powder for Injection
Date of Approval: November 9, 2023 Treatment for: Thrombotic Thrombocytopenic Purpura Press Release | Approval History
- Zepbound (tirzepatide) Injection
Date of Approval: November 8, 2023 Treatment for: Weight Loss (Obesity/Overweight) Press Release | Approval History
- Fruzaqla (fruquintinib) Capsules
Date of Approval: November 8, 2023 Treatment for: Colorectal Cancer Press Release | Approval History
- Zituvimet (metformin hydrochloride and sitagliptin) Tablets
Date of Approval: November 3, 2023 Treatment for: Diabetes, Type 2 Press Release | Approval History
- Voquezna (vonoprazan) Tablets
Date of Approval: November 1, 2023 Treatment for: Erosive Esophagitis Press Release | Approval History
|
---|
|
New Indications and Dosage Forms Drugs that have gained FDA approval for the treatment of additional diseases/conditions or new dosage forms/regimens.
|
---|
|
This information is not intended to be medical advice. You should contact your physician before making any changes to your health care. Drugs.com is not responsible for content provided by third-party websites. The Editorial Team, Drugs.com
|
---|
|
| |
|